Pipeline
Today, Alexion's research and development efforts continue to build on the company's
expertise in complement inhibition and antibody development, particularly in three main areas:
- Continuing support of the company's PNH programs to expand knowledge of the disease including
its diagnosis, clinical consequences and optimal treatment, with the goal of reducing
the complications and risks associated with the disease.
- Investigating Soliris® (eculizumab) as a potential treatment for patients with
other life-threatening and often rare diseases in which complement activation plays
a role and where current treatment options remain inadequate.
- Building Alexion's oncology program through the development of our anti-CD200 antibody as a potential treatment for patients
with hematological malignancies and solid tumors.